If you or someone close to you lives with schizophrenia or bipolar I disorder, you already know that finding the right medication is not a one-and-done decision. In India, the National Mental Health Survey (2015-16) conducted by NIMHANS estimated that nearly 150 million Indians need mental healthcare interventions, yet 83 out of every 100 people with a mental health condition do not have access to adequate care. [5] When treatment options are already limited, every new medication that enters the landscape deserves a thorough, honest look.
BYSANTI (Milsaperidone) is a newly approved atypical antipsychotic. Developed by Vanda Pharmaceuticals and granted FDA approval in February 2026, it is classified as a new chemical entity, meaning it has its own distinct molecular structure, even though it rapidly converts to and from iloperidone once inside the body. This is why the FDA approved it separately rather than treating it as a reformulation of an existing drug. [4] Bysanti (milsaperidone) is an oral atypical antipsychotic taken twice daily, approved for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder in adults.
Key Insights
- Understand what BYSANTI is: an atypical antipsychotic approved by the U.S. FDA in February 2026 for schizophrenia and bipolar I mania in adults. [1]
- Know how it works: it blocks dopamine D2 and serotonin 5-HT2 receptors and converts to iloperidone in the body. [3]
- Be aware of key risks: side effects include dizziness, dry mouth, weight gain, and heart rhythm changes, with a boxed warning for older adults with dementia-related psychosis. [1]
- Recognise the role of genetic testing: people who process the drug more slowly may need lower doses, so testing before starting may be recommended by your doctor. [1]
How Does Milsaperidone Work in the Brain?
Quick Answer: The milsaperidone mechanism of action involves blocking dopamine D2 and serotonin 5-HT2 receptors. Once ingested, milsaperidone rapidly interconverts with iloperidone, meaning both compounds actively regulate the chemical signals involved in psychosis and mood instability. [3]
Your brain relies on chemical messengers, mainly dopamine and serotonin, to manage your thoughts, mood, perception, and behaviour. In schizophrenia, dopamine becomes overactive in certain areas, which is what produces hallucinations, delusions, and confused thinking. In bipolar I disorder, shifts in these same chemical systems drive the extreme highs of manic episodes. [1]
Newer antipsychotics, including milsaperidone, work by targeting several of these chemical systems at once, not just dopamine. This broader approach is what makes them different from older medications, which focused mainly on dopamine and often caused stiffness, tremors, and involuntary movements as a result. [3]
Milsaperidone also binds strongly to alpha-1 adrenergic receptors, which researchers believe may help manage agitation and hyperarousal. [3] Understanding how does milsaperidone work matters because the way the drug interacts with your brain's receptors directly shapes both its benefits and its side effects:
| Receptor Target | Role in Treatment |
|---|---|
| Dopamine D2 | Reduces hallucinations, delusions, and disorganised thinking |
| Serotonin 5-HT2 | Helps regulate mood and lowers the risk of movement-related side effects |
| Alpha-1 adrenergic | May reduce agitation and hyperarousal; also linked to orthostatic hypotension risk |
| Histamine H1 | Associated with sedation and weight gain as side effects |
What Conditions Is BYSANTI Approved to Treat?
Quick Answer: BYSANTI uses two approved indications in adults: the treatment of schizophrenia and the acute treatment of manic or mixed episodes in bipolar I disorder. It is not approved for children, adolescents, maintenance therapy in bipolar disorder, or elderly individuals with dementia-related psychosis. [1]
New drugs for bipolar Bysanti (milsaperidone) was approved by the FDA in February 2026 as a new atypical antipsychotic for adults experiencing acute manic or mixed episodes in bipolar I disorder, adding another option alongside treatments such as lithium, valproate, and other second-generation antipsychotics. [1]
The REPRIEVE trial, a long-term relapse prevention study of iloperidone (the drug milsaperidone converts to), showed that people who continued iloperidone experienced significantly fewer relapses than those switched to placebo. [2] In shorter iloperidone trials lasting 4 to 6 weeks, individuals showed meaningful reductions in psychotic symptoms measured by standardised clinical scales: PANSS (which tracks the severity of positive and negative symptoms) and BPRS (which measures overall psychiatric severity). Improvement typically began within the first 4 weeks of treatment. [2]
| Study Detail | Result |
|---|---|
| Relapse rate (continued treatment) | Approximately 20% |
| Relapse rate (switched to placebo) | Approximately 63% |
| Average time to relapse (treatment group) | ~139 days |
| Average time to relapse (placebo group) | ~71 days |
Source: REPRIEVE trial data, as reported via iloperidone studies [2]
For Indian people and families, this data matters because relapse is one of the most common reasons for repeated hospitalisation across psychiatric facilities in the country. Recent antipsychotic drugs, including second-generation antipsychotics such as milsaperidone, treat conditions such as schizophrenia and bipolar disorder by acting on multiple neurotransmitter pathways. [3]
What Are the Side Effects and Precautions You Should Know?
Quick Answer: The most commonly reported milsaperidone side effects include dizziness, dry mouth, fatigue, nasal congestion, racing heartbeat, and weight gain. Serious risks include QTc prolongation, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, and seizures. [1]
| Category | Schizophrenia | Bipolar I Disorder |
|---|---|---|
| Most common | Dizziness, dry mouth, fatigue, nasal congestion, weight gain | Racing heartbeat, dizziness, dry mouth, raised liver enzymes, low blood pressure, weight gain |
| Weight gain (4-6 week trials) | Average 2.7 kg above placebo | Average 3.2 kg above placebo |
Serious side effects that require immediate medical attention:
- QTc prolongation (heart rhythm changes), which can be life-threatening in severe cases, fainting or a racing or irregular heartbeat needs emergency care, call 112
- Neuroleptic malignant syndrome (NMS): high fever, rigid muscles, confusion, sweating - call 112 or go to the nearest emergency department immediately
- Tardive dyskinesia: uncontrollable facial or body movements that may become permanent
- Metabolic changes: elevated blood sugar, cholesterol, and triglycerides
- Orthostatic hypotension: sudden blood pressure drops when standing, especially during early treatment
Source: Bysanti Prescribing Information, as reported on Drugs.com [1]
Milsaperidone precautions are worth discussing thoroughly before starting. Individuals with severe liver impairment should not take BYSANTI. Those with a history of seizures, cardiovascular conditions, or low white blood cell counts need closer monitoring.
Certain medications that affect how your liver processes drugs, known as CYP2D6 or CYP3A4 inhibitors (for example, fluoxetine, paroxetine, or ketoconazole), can slow down how your body breaks down milsaperidone, potentially increasing the risk of side effects. All current medications and supplements should be disclosed to the prescribing psychiatrist before starting treatment. [1]
If you or your loved one is pregnant, exposure during the third trimester carries a risk of movement-related and withdrawal symptoms in the newborn. Breastfeeding is not recommended during treatment and for at least 6 days after the last dose (8 days if your body processes the drug more slowly). [1]
What Does the Dosing Schedule Look Like?
Quick Answer: Milsaperidone dosage begins at 1 mg twice daily and is gradually increased (a process called titration, where the dose is raised in small steps to find the right level while keeping side effects to a minimum). The maintenance dose range for schizophrenia is 6 to 12 mg twice daily. Genetic testing for CYP2D6 status may be recommended before starting treatment. [1]
Increasing the dose gradually reduces the risk of orthostatic hypotension, one of the most common early side effects, which is why doses should only be adjusted by the prescribing psychiatrist.
| Dosing Detail | Specification |
|---|---|
| Starting dose | 1 mg twice daily |
| Titration | Gradual increase over several days |
| Maintenance range (schizophrenia) | 6-12 mg twice daily |
| Administration | Oral tablet, with or without food |
| Available strengths | 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg |
| CYP2D6 poor metabolisers | Require lower doses on a modified schedule |
| Titration packs | Pack A (schizophrenia), Pack B (bipolar I), Pack C (poor metabolisers / concurrent CYP inhibitors) |
Source: Drugs.com [1]
If your body breaks down the drug more slowly than average (what doctors call being a "poor metaboliser" or "slow metaboliser"), standard doses may build up in your system and raise the risk of side effects. [2] In India, where pharmacogenomic testing is not yet routine in most psychiatric settings, discussing this screening with your psychiatrist is worth raising, particularly if previous antipsychotics caused unexpected side effects.
Psychiatric Care at Jagruti Rehabilitation Centre
For anyone starting or switching antipsychotic medication, the first few weeks of treatment require close clinical attention that outpatient visits alone may not provide. At Jagruti Rehabilitation Centre, the psychiatric team supports patients through this critical phase with a residential programme combining medical oversight, therapeutic support, and daily monitoring.
Care during this period includes:
- Psychiatric assessment and daily medication review during the stabilisation phase
- Therapy alongside medication, so psychological and pharmacological support work together
- Family involvement from early in the treatment process
- Daily routines covering meals, sleep, physical activity and rest: all designed to support stability
Jagruti operates residential psychiatric centres across multiple cities in India, including a mental hospital in Bangalore. Medications like BYSANTI reflect real progress in psychiatric treatment, but they work best within a broader clinical framework. If you or your family is navigating a new diagnosis or a medication change, residential psychiatric care can provide the consistency that this period demands. Recovery is possible with the right support; for urgent help, call Tele MANAS on 1-800-891-4416.
